Catalys Pacific is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative medicines for patients in Asia and around the world. The company leverages its expertise in clinical development and regulatory know-how to bring therapies to market, with an emphasis on addressing unmet medical needs.

Catalys Pacific

Leveraging its networks in academia, biotech, venture capital and the pharmaceutical industry, Catalys Pacific has assembled a group of Strategic and Preferred Partners with whom to create asset-centric global bioventure companies.
Catalys Pacific begins operations as one of Japanʼs largest life sciences-focused investment firms. The firmʼs mission is to provide solutions to unmet medical needs for patients worldwide by creating and investing in companies that drive innovation in life sciences. Catalys Pacific maintains a strictly independent governance structure that ensures autonomous assessment and decision-making of its investments.

HilleVax

Mineralys Therapeutics

Phathom Pharmaceuticals

Phathom Pharmaceuticals, a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced VOQUEZNA® (#vonoprazan) tablets for Erosive GERD and associated heartburn added to Express Scripts' national formularies.

#Phathom #GERD 

Read the release to learn more: 
https://lnkd.in/gq8QaDgw

Transposon Therapeutics, a biotechnology company developing a platform of novel, orally administered therapies for the treatment of neurodegenerative and aging-related diseases, announced final results from a Phase 2 study of TPN-101 for the treatment of Progressive Supranuclear Palsy and interim results from a Phase 2 study of TPN-101 for the treatment of C9orf72-related Amyotrophic Lateral Sclerosis and/or Frontotemporal Dementia.

#Transposon #PSP #ALS #FTD 

Read the release to learn more: 
https://lnkd.in/gtFgTrTw

Mineralys Therapeutics, a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease and other diseases driven by abnormally elevated aldosterone, announced $120 Million Private Placement Financing.

#Mineralys #PIPE 

Read the release to learn more: 
https://lnkd.in/g9DDsZiF

Today Renalys Pharma, Inc. was launched for developing medicines and treatments for Asian patients with renal disease.

Renalys Pharma’s efforts are centered on bringing #sparsentan, an investigational dual-acting treatment developed by #Travere Therapeutics, to IgA nephropathy patients in Japan and selected Asian countries. 

#IgAN

Read the release to learn more: 
https://lnkd.in/gPXz-e7V


We are pleased to announce that Mr. Ryutaro Shimazaki, a former Executive Officer at Kyowa Kirin Co., Ltd., has joined the team as a Partner.

He will contribute to our #inbound strategy to create new #biotech companies in Japan and to eliminate the drug lag between Japan and other countries through new #drug development.

See our release for more information:
https://lnkd.in/gifZ66Kf

msh id	COM:CATALYSPACIFIC
symbol	-
name	Catalys Pacific
homepage url	https://catalyspacific.com
country	JP
sector	Healthcare & Health Services
industry	Biotechnology
market	PRIVATE
employee count	8
crunchbase url	https://www.crunchbase.com/organization/catalys-pacific
linkedin url	https://www.linkedin.com/company/catalys-pacific
founders	-

market cap	-
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	5.66
growth score 28	51.09
growth score 90	13.1
growth score 365	3.96

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	-
growth cost of revenue	-
growth depreciation and amortization	-
growth ebitda	-
growth ebitda ratio	-
growth eps	-
growth eps diluted	-
growth general and administrative expenses	-
growth gross profit	-
growth gross profit ratio	-

COM:CATALYSPACIFIC

Catalys Pacific

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	-
cost of revenue	-
depreciation and amortization	-
ebitda	-
ebitda ratio	-
eps	-
eps diluted	-
operating expenses	-
operating income	-
operating income ratio	-

accounts receivables	-
capital expenditure	-
cash at beginning of period	-
cash at end of period	-
inventory	-
working capital ttm	-

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-